arrow
M

Michiel Strijbos

zas
H指数:21
被引数:1,871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial

前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描的分期迁移与常规影像学比较:接受放射治疗的高风险前列腺癌患者的THUNDER试验II/III期研究结果

2025-09-250
OAAI
Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial

卡铂在转移性去势抵抗性前列腺癌患者中的疗效:来自生物标志物驱动的、随机、结果适应性ProBio试验的结果

2024-09-011
PRE
Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial

循环肿瘤DNA比例在转移性去势抵抗性前列腺癌中的预后价值:ProBio试验的见解

2024-09-010
PRE
Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial

雄激素受体通路抑制剂与紫杉烷类药与标准治疗在转移性去势抵抗性前列腺癌中的健康相关生活质量结局:ProBio试验结果

2024-09-010
PRE
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial (Aug, 10.1038/s41591-024-03204-2, 2024)
2024-08-280
OAAI
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

雄激素受体途径抑制剂和紫杉烷类药物在转移性前列腺癌中的应用: 一项结果适应性随机平台试验

2024-08-201
OAAI
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

TP53优于其他雄激素受体生物标志物,可预测转移性去势抵抗性前列腺癌的阿比曲酮或恩扎鲁他胺的预后

2019-03-15132
OAAI
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

转移性前列腺癌的无细胞DNA分析揭示了微卫星不稳定性,结构重排和克隆造血

2018-11-2195
OAAI
Global cancer control: responding to the growing burden, rising costs and inequalities in access

全球癌症控制: 应对日益增加的负担、成本上升和获取不平等

2018-01-01188
OAAI
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

欧洲年轻肿瘤学家的职业倦怠: 欧洲医学肿瘤学会 (ESMO) 年轻肿瘤学家委员会倦怠调查的结果

2017-07-0196
OAAI